Trial Profile
A Phase I, single centre, open label, escalating dose study to assess the safety, tolerability and immunogenicity of a therapeutic Human Papilloma Virus (HPV) DNA vaccine (AMV002) for HPV-associated head and neck cancer (HNC) after curative treatment
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Mar 2021
Price :
$35
*
At a glance
- Drugs AMV-002 (Primary)
- Indications Human papillomavirus infections; Oropharyngeal cancer; Squamous cell cancer
- Focus Adverse reactions; First in man
- Sponsors Admedus Immunotherapies
- 01 Mar 2021 Results published in the Cancer Immunology Immunotherapy
- 24 Jan 2020 Status changed from not yet recruiting to completed.
- 31 Jan 2018 Status changed from planning to not yet recruiting.